Nasal spray peptides: clever delivery or clever marketing?

What did @extension.health actually say?

The creator is promoting a telehealth platform that sells nasal spray peptide formulas as an alternative to injections. They claim peptides "do cross the nasal mucosa and get into your system close to the brain" and that four spray formulas, each containing two peptides, can help with anxiety, sleep, immune function, and sexual arousal. They acknowledge subcutaneous injection is "always a gold standard" but position nasal delivery as a legitimate second option for needle-averse patients. That framing is worth examining closely, because the gap between "works" and "works as well" is where a lot of the marketing slippage happens here.

Does the science back this up?

Partially, but the creator is glossing over some significant absorption and bioavailability problems. Nasal delivery of peptides is a real and studied route, but efficacy varies enormously depending on the specific peptide, molecular weight, and formulation. Some peptides genuinely do show meaningful intranasal bioavailability. Semax and selank, both Russian-developed neuropeptides, were specifically designed for intranasal use and have human data supporting CNS activity via this route (Eremin et al., 2005, Neuroscience and Behavioral Physiology). PT-141 (bremelanotide), a melanocortin agonist relevant to sexual arousal, was originally studied as a nasal spray before being reformulated as a subcutaneous injection after bioavailability concerns (Diamond et al., 2004, Journal of Sex and Marital Therapy). The creator does not name the specific peptides in each formula, which makes independent verification of the science essentially impossible. That is a real problem.

What did they get wrong (or right)?

Credit where it is due: saying subcutaneous is "the gold standard" is accurate and honest. Most peptide researchers would agree. The claim that peptides "cross the nasal mucosa and get into your system close to the brain" is broadly true for certain peptides via the olfactory pathway, but the creator presents this as a general rule that applies to their unnamed formulas, which it may not. Larger peptides like BPC-157 or TB-500 have poor intranasal bioavailability data compared to smaller neuropeptides. Without knowing what is in each spray, you cannot evaluate whether "close to the brain" absorption is actually relevant to the claimed effects. The phrase "close to the brain" also subtly implies superior CNS delivery, which is doing more marketing work than scientific work in this context.

• Accurate: subcutaneous injection outperforms nasal delivery for most peptides
• Mostly accurate: some peptides do cross nasal mucosa with meaningful bioavailability
• Misleading: implying this applies broadly without naming the specific peptides or citing formulation data
• Unverifiable: the two-peptide-per-formula claim cannot be evaluated without a full ingredient disclosure

What should you actually know?

Nasal peptide delivery is not snake oil, but it is not a simple swap for injections either. The FDA has not approved any compounded peptide nasal spray for the indications listed here. Regulatory status matters: compounded formulations are not equivalent to FDA-approved drugs, and the quality, sterility, and dosing consistency of compounded nasal sprays can vary between pharmacies. If you are considering a nasal peptide product from any telehealth platform, the minimum questions to ask are: what specific peptides are in this formula, what peer-reviewed bioavailability data exists for each peptide via intranasal administration, and which compounding pharmacy is preparing it under what quality standards. The creator does not answer any of these in the video. That gap between compelling branding and clinical transparency is worth paying attention to.